Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus gemcitabine and S-1 for first-line unresectable or metastatic biliary tract cancer
ChiCTR2400085490Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, gemcitabine and tegafur in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective response rate. Started Jun 2024; status: recruiting.
02
Drugs
cadonilimabgemcitabinetegafur
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400085490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085490.